Medibank Private (MPV) AI Stock Analysis

Medibank Private

(Frankfurt:MPV)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Steady Revenue GrowthThe company has maintained a steadily rising revenue base, reaching 9.33B in 2026 with mid-single-digit growth. For an insurer, sustained premium expansion supports scale, strengthens the recurring earnings base, and provides capacity to fund member services and operational investment.

Negative Factors

Operating Profit VolatilityMeaningful swings in operating profitability make future earnings less predictable, even though overall margins remain solid. Sensitivity to pricing, claims, and cost cycles can pressure results when premium increases do not fully offset changes in healthcare utilization or operating expenses.

Medibank Private (MPV) vs. iShares MSCI Germany ETF (EWG)

Market Cap: EUR 10.74B
Dividend Yield: 3.17%
Average Volume (3M): 900
Price to Earnings (P/E): 22.1
Beta (1Y): 0.29
Revenue Growth: 6.78%
EPS Growth: 23.70%
Country: Germany
Employees: 5,001
Sector: Financial
Sector Strength: 68
Industry: Insurance - Life

Medibank Private Business Overview & Revenue Model

Company Description

Medibank Private Limited (MPL.AX) is an Australian firm offering private health insurance alongside a variety of health services. The company operates through two primary divisions. Its Health Insurance division provides a comprehensive suite of priv...

Medibank Private Earnings Call Summary

Earnings Call Date:Feb 17, 2026(Q2-2026)|% Change Since:16.83%|Next Earnings Date:Feb 23, 2027

Earnings Call SentimentPositive

The call conveyed positive operational momentum and strategic progress: group operating profit rose 6%, Medibank Health delivered strong double-digit revenue and profit growth, policyholder growth improved and the company completed a transformative primary care acquisition while maintaining a strong capital position and lifting the interim dividend. Headwinds exist—expense inflation, a revenue-mix shift toward lower-tier products, elevated claims dynamics in extras, negative hospital utilization (partly COVID-driven), lower investment income and competitive pressure from aggregators—but management presented mitigation plans, unchanged guidance ranges, and clear capacity to invest further in health businesses. Overall, the positives (earnings growth, Medibank Health acceleration, M&A scale, capital strength and customer engagement) outweigh the manageable near-term challenges.

Positive Updates

Group earnings growth

Group operating profit increased 6% to $381.7m; underlying EPS (normalizing investment returns) was $0.108 per share, broadly in line with prior year.

Negative Updates

Higher operating expenses and reinvestment

Operating expenses increased 5.4% to $329.4m; expense ratio was 7.7% (up 10bps). FY '26 expense guidance is $690m–$695m, reflecting inflation, volume impacts and continued investment (partially offset by targeted productivity savings).

Company Guidance

Medibank kept FY‑26 guidance largely unchanged: resident claims per policy unit growth of 2.6–2.9% and an expectation that 1H revenue‑mix headwind (~150bps) will be better for the full year; group operating expenses of $690–695m for FY‑26 (including $10m of productivity savings) and non‑recurring cyber/IT security costs of ~ $35m; Medibank Health organic operating profit to grow in FY‑26 broadly in line with 1H26 plus ~A$6m from the Better Medical acquisition in 2H, with a FY‑30 Medibank Health earnings aspiration of at least A$200m and capacity to raise Tier‑2 debt; capital remains strong at 1.9x PCA and a 13.8% capital ratio (above the 10–12% target while holding capital against a A$250m APRA adjustment); interim dividend A$0.083 per share (up 6.4%, 76.8% payout of underlying NPAT); underlying EPS A$0.108 and underlying net investment return 2.74% (annualized spread to RBA cash rate 184bps).

Medibank Private Peers Comparison

Overall Rating

UnderperformOutperform

Sector (68)

Financial Indicators

DE:MPV against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	68Neutral	$18.00B	11.42	9.92%	3.81%	9.73%	1.22%
AU:NHF	64Neutral	AUD 3.24B	17.39	16.75%	4.17%	5.26%	-6.54%

* Financial Sector Average

Performance Comparison

DE:MPV and its peers over the selected period
Show on chart	Ticker	Company Name	Price	Change	% Change
	DE:MPV	Medibank Private Ltd.	3.18	0.55	21.10%
	AU:NHF	NIB Holdings Ltd	6.61	-0.42	-5.92%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Medibank Private AI Stock Analysis